These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 6193402)
21. Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate. Yu YZ; Gong ZW; Ma Y; Zhang SM; Zhu HQ; Wang WB; Du Y; Wang S; Yu WY; Sun ZW Vaccine; 2011 Aug; 29(35):5978-85. PubMed ID: 21718736 [TBL] [Abstract][Full Text] [Related]
22. Experiences in the production of human monoclonal antibodies to tetanus toxoid. Boyd JE; Hastings I; Farzad Z; James K; McClelland DB Dev Biol Stand; 1984; 57():93-8. PubMed ID: 6526155 [TBL] [Abstract][Full Text] [Related]
23. Protective murine monoclonal antibodies to tetanus toxin. Shang HF; Liau MY; Chow MF; Jiang SY; Chen SC; Yeh MY Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1988 Nov; 21(4):199-209. PubMed ID: 3151481 [TBL] [Abstract][Full Text] [Related]
24. Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C. Yousefi M; Tahmasebi F; Younesi V; Razavi A; Khoshnoodi J; Bayat AA; Abbasi E; Rabbani H; Jeddi-Tehrani M; Shokri F J Immunotoxicol; 2014; 11(1):28-34. PubMed ID: 23369087 [TBL] [Abstract][Full Text] [Related]
26. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. Amuguni H; Lee S; Kerstein K; Brown D; Belitsky B; Herrmann J; Keusch G; Sonenshein A; Tzipori S Microbes Infect; 2012 May; 14(5):447-56. PubMed ID: 22198093 [TBL] [Abstract][Full Text] [Related]
27. Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid. Johnston L; Mawas F; Tierney R; Qazi O; Fairweather N; Sesardic D Hum Vaccin; 2009 Apr; 5(4):230-6. PubMed ID: 18948742 [TBL] [Abstract][Full Text] [Related]
28. [In vitro immunization for the production of antibodies to tetanus toxin and toxoid. 2. Antibody production in lymphocyte cultures]. Jahn S; Kiessig ST; Grunow R; von Baehr R Allerg Immunol (Leipz); 1987; 33(2):89-94. PubMed ID: 2959130 [TBL] [Abstract][Full Text] [Related]
29. Anti-tetanus toxoid antibody production and protection against lethal doses of tetanus toxin in hu-PBL-SCID mice. Naito S; Okada Y; Takahashi M; Kato H; Taneichi M; Ami Y; Suzaki Y; Oka T; Okuma K; Morokuma K; Onodera H; Inoue M; Takahashi Y; Yamazaki S; Kimura H; Komuro K; Uchida T Int Arch Allergy Immunol; 2000 Oct; 123(2):149-54. PubMed ID: 11060487 [TBL] [Abstract][Full Text] [Related]
30. Epitope Mapping of Tetanus Toxin by Monoclonal Antibodies: Implication for Immunotherapy and Vaccine Design. Ghotloo S; Golsaz-Shirazi F; Amiri MM; Jeddi-Tehrani M; Shokri F Neurotox Res; 2020 Feb; 37(2):239-249. PubMed ID: 31410686 [TBL] [Abstract][Full Text] [Related]
31. Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccines-part 1. Winsnes R; Sesardic D; Daas A; Behr-Gross ME Pharmeuropa Bio; 2004 Jan; 2003(2):35-68. PubMed ID: 14960262 [TBL] [Abstract][Full Text] [Related]
32. Neutralization of tetanus toxin by human and rabbit immunoglobulin classes and subunits. Ourth DD; MacDonald AB Immunology; 1977 Dec; 33(6):807-15. PubMed ID: 590997 [TBL] [Abstract][Full Text] [Related]
33. Comparative human and mouse antibody responses against tetanus toxin at clonal level. Yousefi M; Younesi V; Bayat AA; Jadidi-Niaragh F; Abbasi E; Razavi A; Khosravi-Eghbal R; Asgarian-Omran H; Shokri F J Immunotoxicol; 2016; 13(2):243-8. PubMed ID: 25990600 [TBL] [Abstract][Full Text] [Related]
34. Studies on the antibody composition and neutralizing activity of tetanus antitoxin sera from various species of animals in relation to the antigenic substructure of the tetanus toxin molecule. Matsuda M; Makinaga G; Hirai T Biken J; 1983 Dec; 26(4):133-43. PubMed ID: 6204634 [TBL] [Abstract][Full Text] [Related]
35. Relation between protective potency and specificity of antibodies in sera of tetanus immunized individuals. German-Fattal M; German A; Bizzini B Eur J Epidemiol; 1987 Jun; 3(2):119-22. PubMed ID: 3301392 [TBL] [Abstract][Full Text] [Related]
36. Structural basis of tetanus toxin neutralization by native human monoclonal antibodies. Wang Y; Wu C; Yu J; Lin S; Liu T; Zan L; Li N; Hong P; Wang X; Jia Z; Li J; Wang Y; Zhang M; Yuan X; Li C; Xu W; Zheng W; Wang X; Liao HX Cell Rep; 2021 May; 35(5):109070. PubMed ID: 33951441 [TBL] [Abstract][Full Text] [Related]
37. Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin. Tsuzuki K; Yokosawa N; Syuto B; Ohishi I; Fujii N; Kimura K; Oguma K Infect Immun; 1988 Apr; 56(4):898-902. PubMed ID: 2450068 [TBL] [Abstract][Full Text] [Related]
38. Polyspecific human and murine antibodies to diphtheria and tetanus toxoids and phospholipids. Sutjita M; Hohmann A; Comacchio R; Bradley J Clin Exp Immunol; 1988 Aug; 73(2):191-7. PubMed ID: 3263226 [TBL] [Abstract][Full Text] [Related]
39. Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell. Chin J; Sohn Y; Lee SH; Park YI; Choi MJ Biologicals; 2003 Mar; 31(1):45-53. PubMed ID: 12623059 [TBL] [Abstract][Full Text] [Related]
40. A human monoclonal antibody specific for tetanus toxoid. Olsson L; Mazauric T; Vincent-Falquet JC; Armand J Dev Biol Stand; 1984; 57():87-91. PubMed ID: 6526153 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]